Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

129

Full text

111

Free full text

Publication Types

Journal Article

134

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Review

Clinical Trial

Multicenter Study

Comparative Study

Case Reports

Observational Study

Clinical Trial, Phase III

Meta-Analysis

Clinical Trial, Phase II

Research Support, N.I.H., Extramural

Controlled Clinical Trial

Systematic Review

Research Support, U.S. Gov't, Non-P.H.S.

Clinical Trial, Phase I

Research Support, U.S. Gov't, P.H.S.

Evaluation Study

Practice Guideline

Clinical Trial, Phase IV

Equivalence Trial

Publication Year

From

Quick links

Individual year

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Epoetin Alfa""[mesh_terms]

134 Results

Searching titles within these results

Endocrinological disorders in acute kidney injury: an often overlooked field of clinical research.

Mehmet Kanbay, Sidar Copur, Carlo Basile, Atalay Demiray

Journal of nephrology 2023;36(3):885-893

Full Text

Abstract

ESAs and irons in the pipeline: how do they differ?

Anatole Beserab

Nephrology news & issues 2013;27(7):Supp 6-9

Full Text

Is intravenous ascorbic acid an effective and safe option for increasing hemoglobin levels in patients with a hyporesponse to epoetin alfa?

Tamara M Kear

Nephrology nursing journal : journal of the American Nephrology Nurses' Association 2012;39(2):137-40

Full Text

Abstract

How to optimise anaemia therapy in peritoneal dialysis patients.

Iain C Macdougall

Contributions to nephrology 2006;150():202-213

Full Text

Abstract

An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease.

Hanxue Zhao, Peiyun Li, Hong-Liang Zhang, Linpei Jia

Renal failure 2023;45(2):2258986

Free Full Text

Abstract

The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy.

Christian Thomas, Andreas Kirschbaum, Dieter Boehm, Lothar Thomas

Medical oncology (Northwood, London, England) 2006;23(1):23-36

Full Text

Abstract

Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.

Patricia A Ford, Jason Mastoris

Transfusion 2004;44(12 Suppl):15S-25S

Full Text

Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.

Dorota Drozdz, Bradley A Warady, Sylvie Meyer Reigner, Chitra Tirodkar

American journal of kidney diseases : the official journal of the National Kidney Foundation 2023;81(6):684-694.e1

Full Text

Abstract

Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level.

Jaime Sanz Ortiz

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2008;10(8):486-92

Full Text

Abstract

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.

Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, Amer M Zeidan, Rami S Komrokji, Jake Shortt, David Valcarcel, Anna Jonasova, Sophie Dimicoli-Salazar, Ing Soo Tiong, Chien-Chin Lin, Jiahui Li, Jennie Zhang, Ana Carolina Giuseppi, Sandra Kreitz, Veronika Pozharskaya, Karen L Keeperman, Shelonitda Rose, Jeevan K Shetty, Sheida Hayati, Sadanand Vodala, Thomas Prebet, Andrius Degulys, Stefania Paolini, Thomas Cluzeau, Pierre Fenaux, Guillermo Garcia-Manero

Lancet (London, England) 2023;402(10399):373-385

Full Text

Abstract

Pharmacist's role in managing anemia in patients with chronic kidney disease: potential clinical and economic benefits.

Cheryl Gilmartin

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2007;64(13 Suppl 8):S15-22; quiz S23-5

Full Text

Abstract

The impact of anemia and its treatment on patients with gynecologic malignancies.

Susana Campos

Seminars in oncology 2002;29(3 Suppl 8):7-12

Full Text

Abstract

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update.

J Douglas Rizzo, Mark R Somerfield, Karen L Hagerty, Jerome Seidenfeld, Julia Bohlius, Charles L Bennett, David F Cella, Benjamin Djulbegovic, Matthew J Goode, Ann A Jakubowski, Mark U Rarick, David H Regan, Alan E Lichtin

Blood 2008;111(1):25-41

Free Full Text

Abstract

Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study .

Gérard London, Johannes Mann, David Goldsmith, Christian Combe, Frank Dellanna, Philippe Zaoui, Nadja Hoebel, Andriy Krendyukov, Karen MacDonald, Ivo Abraham

Clinical nephrology 2018;89 (2018)(1):1-9

Free Full Text

Abstract

Detection of erythropoietin misuse by the Athlete Biological Passport combined with reticulocyte percentage.

Thomas Christian Bonne, Niels Vidiendal Olsen, Nikolai Baastrup Nordsborg, Jacob Bejder, Niels Jacob Aachmann-Andersen

Drug testing and analysis 2017;8(10):1049-1055

Full Text

Abstract

Results: 1 – 15 / 134

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Epoetin Alfa""[mesh_terms]

Endocrinological disorders in acute kidney injury: an often overlooked field of clinical research.

ESAs and irons in the pipeline: how do they differ?

Is intravenous ascorbic acid an effective and safe option for increasing hemoglobin levels in patients with a hyporesponse to epoetin alfa?

How to optimise anaemia therapy in peritoneal dialysis patients.

An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease.

The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy.

Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.

Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.

Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level.

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.

Pharmacist's role in managing anemia in patients with chronic kidney disease: potential clinical and economic benefits.

The impact of anemia and its treatment on patients with gynecologic malignancies.

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update.

Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study .

Detection of erythropoietin misuse by the Athlete Biological Passport combined with reticulocyte percentage.

Results for
""Epoetin Alfa""[mesh_terms]

Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study .